Provectus’ PV-10 Offers Hope for Melanoma Patients
Provectus Pharmaceuticals, Inc. (PVCT), which is developing cancer treatments alongside companies like Dendreon Corporation (DNDN) and Genta Incorporated (GETA), is now preparing for Phase III trials for its PV-10 treatment for Melanoma.
The nationally syndicated ABC featured the Rose Bengal-based drug and its success in one patient in a story that aired in 2008. Here is a copy of the ground-breaking ABC report:
CONTACT: 888-288-5215 · Please read our Full Disclaimer pertaining to this article.
Request a Detailed Report on Provectus Pharmaceuticals, Inc. (PVCT)